New York, NY – May 6, 2015 – New York City based securities and corporate law firm Sichenzia Ross Friedman Ference LLP (the “Firm”) announced today that the Firm has represented Laidlaw & CO. (UK) Ltd. as the sole book-running manager of the initial public offering (IPO) of Viking Therapeutics, Inc. (NASDAQ: VKTX). The public offering consisted of 3,000,000 shares of the Company’s common stock at a price to the public of $8.00 per share which resulted in aggregate gross proceeds of $24,000,000 before deducting expenses. Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. The Sichenzia Ross Friedman Ference LLP team was led by Partners Richard A. Friedman and Stephen A. Cohen.
Media Contact
pr@srf.law
(212)-930-9700
- Partner David Manno Quoted in AskTraders Article Discussing Barnes & Noble’s IPO Options - June 23, 2025
- Sichenzia Ross Ference Carmel LLP Represents Shuttle Pharmaceuticals in $4.25 Million Private Placement Priced at the Market Under Nasdaq Rules - June 23, 2025
- Sichenzia Ross Ference Carmel LLP Represents Revere Securities in $8 Million Public Offering of QMMM Holdings - June 23, 2025